MDS is First to Acquire API 5000 Mass Spectrometers

MDS Pharma Services, a provider of innovative drug discovery and development solutions, is the first contract research organization to adopt the new API 5000 mass spectrometer for small molecule quantification studies. Two of the systems have been ordered for use at the business unit's bioanalytical site in Lincoln, Neb.

PharmaLive

(http://www.pharmalive.com/News/index.cfm?articleid=208503&categoryid=20)